Intelligent Bio Solutions Inc. · NASDAQ:INBS
Intelligent Bio Solutions — Investor Presentation (April 2026)
26 slides from Intelligent Bio Solutions's investor presentation, Apr 20, 2026
Slide 1: Pioneering Pain-free Solutions
INTELLIGENT BIO SOLUTIONS Pioneering Pain-free Solutions Transforming drug testing with non-invasive, cost-effective, reliable solutions. NASDAQ: INBS | April 2026
Slide 2: Forward Looking Statements
Forward Looking Statements Certain statements in this presentation may constitute “forward-looking statements" as defined in Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), Section 21E of the Securities Exchange Act of 1934 (the “Exchange Act’), the Private Securities L
Slide 3: We are a medical technology company
We are a medical technology company delivering intelligent, rapid, non-invasive testing solutions. Our mission is to redefine the approach to testing and deliver pain-free, accessible solutions that drive transformative change and improve the quality of life.
Slide 4: Simpler Drug Testing
Slide 5: The journey of a drug through the body
The journey of a drug through the body: Absorption: how the drug moves from the site of administration to the site of action. Distribution: the journey of the drug through the bloodstream to various tissues of the body. Metabolism: the process that breaks down the drug. Excretion: the removal of the
Slide 6: Steps to Simpler Drug Testing
3 Steps to Simpler Drug Testing 1 Donor places the tip of each finger on the fingerprint collection area for 5 seconds. 2 Test administrator inserts the cartridge into the digital reader. 3 In less than 10 minutes the reader provides results*. *INBS has commenced a Validation Study for a rapid drug
Slide 7: Benefits of Fingerprint Drug Testing
Benefits of Fingerprint Drug Testing aN Reduce Risk Aim to identify current impairment rather than past use with a detection window of 16-24 hours. RA ZN Expand Testing Capabilities Conduct screening at any time and location using a compact and portable system. Save Costs Bring drug testing in-house
Slide 8: Intelligent Fingerprinting vs Urine & Saliva Drug Testing
Intelligent Fingerprinting vs Urine & Saliva Drug Testing Fingerprint Detection Window 16-24 hours Up to 2 days Up to 4 days Average Test Time (2-3 Pea a eae Up to 20 minutes 20 minutes - 4 hours or more Average Annual Cost * ~ $5,500 ~ $7,600 ~ $7,750 Accuracy Up to 99% Up to 98% Up to 99% * Based
Slide 9: Our Advantage: Window of Detection
Slide 10: SmarTest Sweat Drug Testing Patch
NASDAQ: INBS. SmarTest Sweat Drug Testing Patch Non-invasive, wearable sweat patch for continuous drug monitoring The Smartest Patch is a discreet, wearable device that enables continuous drug detection over a 7 to 10-day period. Worn on the upper arm, it collects sweat in real time to monitor for a
Slide 11: Drug Testing Panel Capabilities
Drug Testing Panel Capabilities Testing* Smartest Pat: Amphetamines Methamphetamine, Amphetamine Amphetamines Amphetamine, Methamphetamine, MDMA, MDA, MDEA Cocaine Cocaine Cocaine Cocaine, Benzoylecgonine Cannabis THC Cannabis THC Opiates & Opioids Morphine, Codeine, 6-AM, Hydrocodone, Hydromorphone
Slide 12: Market Opportunity
Invasive testing to address global demands. Leveraging intelligent, non- Market Opportuni
Slide 13: Addressing a $400 Billion Substance Abuse Problem
Addressing a $400 Billion Substance Abuse Problem! The global market for Drug Screening was valued at US$12.6 Billion in 2024 and is projected to reach US$31.8 billion by 2030, growing at a CAGR of 16.7%. The Drug Screening Products segment is projected to reach US$16.7 billion by 2030 (CAGR 14%). M
Slide 14: U.S. Market Opportunity
Slide 15: Growing Drug Consumption
Growing Drug Consumption Approximately 316 million people used an illicit drug in 2023, a 28% increase over the last 10 years. PS oO million million million million cannabis users, opioid users, amphetamine users, cocaine users, representing representing 4.6% of the representing 1.2% of the represen
Slide 16: More Than 70% of Those Abusing Alcohol or Illicit Drugs in the US Are Employed
More Than 70% of Those Abusing Alcohol or Illicit Drugs in the US Are Employed! Illicit drugs are increasingly contributing to accidents in the workplace. Drug test positivity post-accident has climbed over the last five years. INBS is working towards FDA clearance of its Intelligent Fingerprinting
Slide 17: Percentage of New and Current Employees Drug Tested
Percentage Of New And Current Employees! Transportation and warehousing Retail trade Wholesale trade Manufacturing Construction Utilities Natural resources and mining Total U.S., private sector 0% 10% 20% 30% 40% 50% 60% "US Bureau of Labor Statistics 2021. Business Response Survey 2021 Charts: Esta
Slide 18: Commercial Traction
i) G E je] 7] J UO
Slide 19: Customer Accounts
Customer Accounts 480+ Active Accounts Across 27 Countries 9 9 Ho NASDAQ: INBS. @ParkerSteel — “dgp, — Blnegarty = fy TotalRecycing = E Hill me COMPLETE STEht 0 ‘i Fasten PREMIERS RobinsonBrothers Over explore o WeCee@ WPRINCELULD (ue @& abellio~ mmeselass We, Paetways Bboughey CROWN | —<—— Ke Seas
Slide 20: Target Sectors
Target Sectors Beyond Safety-Critical Workplace Settings Government + Public safety and compliance initiatives + Border security and customs screening + Workplace safety programs across state agencies + Defense and national security applications = = en + Emergency and frontline workforce testing Law
Slide 21: A&F Sprinklers Testimonial
A&F Sprinklers Testimonial “The process is efficient, seamless, non-invasive, and portable, which is great for us because we have sites all over the country. It’s painless. There are two key results: One, our team is more appreciative of why we do it and it’s talked about more. Two, our non-negative
Slide 22: Financial Overview
RECISION
Slide 23: Summary
Summary NASDAQ: INBS Large growing customer base with 1700+ installed readers and 480+ active customers. Increased revenue and growth, utilizing the Razor/Razor-blade model. Completed multiple milestones as we progress toward planned U.S. market entry. FDA Cut-Off and Penetration studies complete. M
Slide 24: Fiscal H1 2026 Financial Highlights
Fiscal H1 2026 Financial Highlights Q2 Revenue +48% YoY $896,774 Gross Margins at 49% + 10% YoY H1 Revenue +36% YoY $2.01 million Q2 Reader Sales +104% YoY $246,519
Slide 25: Common Stock Issued
Common Stock Issued Warrants Prefunded/Pre-paid Total Common Equivalent Shares Warrants Cashless Warrants (Exercise Price Between $4.10 - $5.00) Warrants Common Stock Equivalent - WAEP. of $26.26 *No ratchets or resets. 2,001,173 1,642,425 3,643,598 27 4,597,700 691,606
Slide 26: Thank You
Thank You www.ibs.inc | info@ibs.inc NASDAQ: INBS 26
Intelligent Bio Solutions — Investor Presentation (April 2026) on 6ix